Cargando…
Angiotensin-Converting Enzyme 2 as the Molecular Bridge Between Epidemiologic and Clinical Features of COVID-19
Autores principales: | Bombardini, Tonino, Picano, Eugenio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Canadian Cardiovascular Society. Published by Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118531/ https://www.ncbi.nlm.nih.gov/pubmed/32299780 http://dx.doi.org/10.1016/j.cjca.2020.03.026 |
Ejemplares similares
-
Angiotensin-converting Enzyme Genetic Polymorphism
por: Wiwanitkit, Somsri, et al.
Publicado: (2014) -
Re: Is there a difference in the effect between the angiotensin‐converting enzyme inhibitor and angiotensin‐receptor blocker on the COVID‐19?
por: Liu, Xiao, et al.
Publicado: (2020) -
Renin Angiotensin Converting Enzyme 2 and COVID-19: Prevention and Treatment
por: Kafami, Marzieh, et al.
Publicado: (2021) -
COVID-19 and angiotensin-converting enzyme inhibitors from plant origin
por: Gharebaghi, Reza, et al.
Publicado: (2022) -
An observed association between angiotensin-converting enzyme 2 polymorphisms and COVID-19 severity in China
por: Wang, Jin, et al.
Publicado: (2022)